Abstract
Corticotropin releasing factor (CRF) receptors belong to the secretin family of G proteincoupled receptors (GPCRs) and are responsible for initiating endocrine stress responses and mediating anxiety related behaviors upon activation via stressors. The main binding site for the CRF ligands is the first extracellular domain (ECD) of the receptors. Several structures of ligand-free and ligand-bound ECDs were recently determined either by nuclear magnetic resonance (NMR) spectroscopy or X-ray crystallography. They reveal how the ligands bind through both hydrophobic and hydrophilic interactions to the ECDs, which is highly dynamic in the absence of ligands. It is the purpose of this review to discuss these structures with a particular focus on ligand-receptor interaction.
Keywords: GPCR, CRF receptors, first extracellular domain, structure, ligand binding, ECD.
Graphical Abstract
Current Molecular Pharmacology
Title:Structures of the First Extracellular Domain of CRF Receptors
Volume: 10
Author(s): Viviane Zelenay, Marilyn Perrin and Roland Riek*
Affiliation:
- Department of Physical Chemistry, ETH Zurich, Vladimir-Prelog-Weg 2, 8093 Zurich,Switzerland
Keywords: GPCR, CRF receptors, first extracellular domain, structure, ligand binding, ECD.
Abstract: Corticotropin releasing factor (CRF) receptors belong to the secretin family of G proteincoupled receptors (GPCRs) and are responsible for initiating endocrine stress responses and mediating anxiety related behaviors upon activation via stressors. The main binding site for the CRF ligands is the first extracellular domain (ECD) of the receptors. Several structures of ligand-free and ligand-bound ECDs were recently determined either by nuclear magnetic resonance (NMR) spectroscopy or X-ray crystallography. They reveal how the ligands bind through both hydrophobic and hydrophilic interactions to the ECDs, which is highly dynamic in the absence of ligands. It is the purpose of this review to discuss these structures with a particular focus on ligand-receptor interaction.
Export Options
About this article
Cite this article as:
Zelenay Viviane, Perrin Marilyn and Riek Roland*, Structures of the First Extracellular Domain of CRF Receptors, Current Molecular Pharmacology 2017; 10 (4) . https://dx.doi.org/10.2174/1874467210666170110120301
DOI https://dx.doi.org/10.2174/1874467210666170110120301 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
MicroRNA Therapeutics: the Next Magic Bullet?
Mini-Reviews in Medicinal Chemistry Future Approaches for Treating Hematologic Disease
Current Pharmaceutical Biotechnology Cancer Kinases and its Novel Inhibitors: Past, Present and Future Challenges
Current Drug Targets Towards Optimal Heart Failure Care: Couples-Oriented Strategies to Improve Patient Adherence and Health Outcomes
Current Cardiology Reviews Sleep and COPD
Current Respiratory Medicine Reviews Neuroinflammation and Alzheimer's Disease: Implications for Microglial Activation
Current Alzheimer Research Chelating Agents for the Treatment of Systemic Iron Overload
Current Medicinal Chemistry Dopamine: Agonists and Neurodegenerative Disorders
Current Drug Targets Cognitive Impairment Associated with Parkinson’s Disease: Role of Mitochondria
Current Neuropharmacology The Role of Vasopressin in Affective Disorders: Possible Targets of Intervention
Central Nervous System Agents in Medicinal Chemistry Recent Developments in the Regulation of Monoamine Oxidase Form and Function: Is the Current Model Restricting Our Understanding of the Breadth of Contribution of Monoamine Oxidase to Brain [dys]Function?
Current Topics in Medicinal Chemistry Ligand and Structure-Based Drug Design as Strategies for the Screening of New BACE1 Inhibitor Candidates
Current Physical Chemistry RETRACTED: Human Suicide, Modern Diagnosis Assistance and Magic Bullet Discovery
Central Nervous System Agents in Medicinal Chemistry Can we Consider Zoledronic Acid a New Antitumor Agent? Recent Evidence in Clinical Setting
Current Cancer Drug Targets Current Drugs and Potential Future Neuroprotective Compounds for Parkinson’s Disease
Current Neuropharmacology Cyclooxygenases in the Central Nervous System: Implications for Treatment of Neurological Disorders
Current Pharmaceutical Design Tolerance Induction by Gene Transfer to Lymphocytes
Current Gene Therapy A Case of Toxic Epidermal Necrolysis Secondary to Acetaminophen in a Child
Current Drug Safety Is Increased Mortality from Alzheimers Disease in Sweden a Reflection of Better Diagnostics?
Current Alzheimer Research Design, Synthesis and In Vitro Biological Evaluation of 3- styrylbenzimidamides as Potential BACE1 Inhibitors
Letters in Drug Design & Discovery